infect
account
around
death
first
year
transplant
bacteri
pathogen
respons
approxim
half
infect
risk
infect
follow
lung
transplant
determin
number
factor
includ
physic
factor
denerv
allograft
result
reduc
cough
reflex
anastomot
site
stenosi
distal
infectionth
net
state
immunosuppress
result
factor
includ
host
immun
system
antireject
immunosuppress
therapi
concomit
viral
infect
cytomegaloviru
contribut
patient
risk
infectionepidemiolog
exposur
organ
includ
donorderiv
infect
commun
acquir
infect
travel
relat
infect
healthcar
associ
infectionsth
use
prophylact
antimicrobi
agent
posttranspl
period
bacteria
defin
morpholog
shape
size
pathogen
bacteri
speci
spheric
cocci
rodshap
bacilli
may
exist
singl
cell
exampl
mani
common
bacilli
pseudomona
stenotrophomona
varieti
characterist
pattern
pneumonia
pair
lancet
shape
cocci
aureu
larg
cluster
cocci
form
bunch
grape
streptococci
long
chain
cocci
whilst
molecular
diagnost
techniqu
polymeras
chain
reaction
pcr
increasingli
import
basi
much
microbiolog
diagnosi
remain
characterist
appear
organ
glass
microscop
slide
stain
dye
varieti
condit
common
stain
includ
gram
stain
first
describ
hc
gram
still
everyday
use
ziehlneelsen
acidfast
stain
mycobacteria
modifi
stain
nocardia
gram
stain
divid
bacteria
gram
posit
gram
neg
depend
abil
cell
wall
prevent
decolouris
stain
crystal
violet
import
rememb
bacteria
aureu
pseudomona
speci
stain
ziehlneelsen
stain
convers
mycobacteria
seen
gram
stain
cultur
techniqu
also
differ
mycobacteria
often
unabl
grow
convent
agar
plate
requir
special
growth
media
prolong
cultur
period
therefor
mycobacteri
infect
suspect
request
form
sampl
must
specifi
mycobacteri
cultur
appropri
investig
perform
laboratori
laboratori
diagnosi
import
bacteria
set
lung
transplant
summaris
tabl
aureu
common
colon
upper
respiratori
tract
skin
isol
increas
frequenc
sputum
patient
cystic
fibrosi
although
frequenc
decreas
age
aureu
acquir
donor
recipi
bacteri
flora
hospit
environ
healthcar
associ
infect
respons
wide
rang
health
careassoci
infect
ventilatorassoci
pneumonia
bactereamia
surgic
site
infect
isol
aureu
characteris
accord
suscept
methicillin
antistaphylococc
penicillin
methicillin
suscept
aureu
mssa
common
commun
acquir
infect
wherea
methicillin
resist
aureu
mrsa
occur
greater
frequenc
hospit
acquir
infect
largest
studi
aureu
follow
lung
transplant
retrospect
singl
centr
studi
conduct
year
period
aureu
infect
develop
lung
transplant
recipi
within
day
transplant
mssa
common
mrsa
proport
mrsa
infect
increas
time
pneumonia
common
infect
follow
tracheobronch
bacteremia
intrathorac
infect
skinsoft
tissu
infect
infect
patient
requir
longer
hospit
intens
care
unit
stay
p
mortal
rate
low
respect
howev
infect
patient
higher
rate
reject
acut
chronic
p
year
p
higher
mortal
p
year
p
dicloxacillin
flucloxacillincefazolin
cephalothin
penicillin
allerg
patient
risk
anaphylaxi
patient
document
penicillin
anaphylaxi
clindamycin
often
prescrib
deep
infect
exhibit
good
tissu
penetr
howev
bacteriostat
antibiot
administ
patient
aureu
bacteraemia
follow
specialist
advic
vancomycin
appropri
therapeut
drug
monitor
tdm
avail
centr
standard
dose
may
inadequ
especi
vancomycin
mrsa
pneumonia
toxic
may
occur
longterm
administr
unless
tdm
undertakensom
isol
may
suscept
clindamycin
cotrimoxazol
doxycyclin
howev
agent
use
treat
bacteraemia
mssa
specif
measur
requir
mrsa
patient
usual
place
contact
precaut
gown
apron
glove
care
hand
hygien
per
moment
hand
hygien
may
isol
singl
room
cohort
colonis
patient
prevent
spread
nonidentifi
colonis
patient
import
respiratori
pathogen
patient
cystic
fibrosi
often
caus
infect
earli
life
replac
organ
pseudomona
spp
time
contrast
patient
undergo
lung
transplant
indic
may
colon
h
influenza
stage
life
posttranspl
infect
h
influenza
rel
uncommon
least
part
wide
spread
practic
administr
azithromycin
trimethoprimsulphamethoxazol
prophylact
agent
postop
period
antimicrobi
agent
activ
h
influenza
therebi
reduc
frequenc
infect
approxim
h
influenza
isol
suscept
ampicillinampicillin
resist
isol
gener
suscept
augmentin
cefuroxim
third
gener
cephalosporin
cefotaxim
ceftriaxon
cephalexin
ineffect
specif
infect
control
measur
requir
standard
precaut
hand
hygien
pneumonia
gener
suscept
penicillinpenicillin
resist
pneumonia
pulmonari
infect
usual
success
treat
penicillin
concentr
achiev
lung
suffici
exceed
threshold
efficacyaltern
treatment
option
penicillin
resist
pneumonia
caus
mening
bloodstream
includ
third
gener
cephalosporin
vancomycin
specif
infect
control
measur
requir
standard
precaut
hand
hygien
guid
laboratori
suscept
test
especi
patient
extens
prior
antibiot
exposuresuscept
test
mucoid
strain
less
reliabl
standard
strainscommonli
use
antibiot
includ
aminoglycosid
gentamicin
tobramycin
amikacin
antipseudomon
betalactam
piperacillintazobactam
ceftazidim
cefepim
ciprofloxacin
meropenem
colistin
may
occasion
requir
extrem
resist
organ
contact
precaut
gener
reserv
patient
multidrug
resist
pseudomona
aeruginosa
trimethoprimsulphamethoxazol
treatment
choic
although
resist
increasingli
describ
ciprofloxacin
activ
approxim
laboratori
isol
specif
infect
control
requir
standard
precaut
hand
hygien
standard
treatment
elimin
bcc
erad
bcc
extrem
difficult
mani
speci
bcc
particularli
b
cenocepacia
intrins
resist
via
varieti
resist
mechan
numer
antimicrobi
agent
includ
aminoglycosid
gentamicin
tobramycin
antipseudomon
betalactam
antibiot
piperacillintazobactam
cefepim
ceftazidim
colistin
rapid
develop
resist
may
occur
therapi
studi
larg
number
bcc
isol
strain
burkholderia
cepacia
complex
isol
cystic
fibrosi
patient
test
resist
avail
antimicrobi
agent
demonstr
isol
activ
agent
minocyclin
meropenem
ceftazidim
inhibit
strain
respect
use
combin
antimicrobi
therapi
overcom
issu
usual
success
bcc
spread
suscept
patient
person
person
contactcontact
contamin
surfac
objectsexposur
bcc
environ
contact
precaut
isol
see
mrsa
may
implement
hospit
altern
patient
colonis
bcc
hous
next
immunosuppress
patient
guidelin
exist
treatment
activ
tb
howev
specif
thing
note
lung
transplant
set
rifamycinbas
regimen
rifampicin
common
drug
use
group
strongli
prefer
steril
capac
abil
prevent
emerg
resist
rifamycin
interact
immunosuppress
agent
dose
adjust
requir
initi
cessat
close
monitor
level
immunosuppress
drug
whilst
receiv
rifamycinsom
centr
prefer
rifabutin
use
transplant
set
less
impact
drug
metabol
rifampicinfor
localis
nonsever
infect
suspicion
isoniazid
resist
fluoroquinolon
could
substitut
rifamycin
durat
extend
month
depend
number
drug
use
otherwis
rifamycin
agent
use
regimenth
minimum
durat
month
expert
prefer
minimum
month
transplant
set
longer
treatment
requir
sever
dissemin
infect
infect
involv
central
nervou
system
andor
bone
joint
pulmonari
diseas
ongo
afb
detect
sputum
month
streptomycin
use
lung
transplant
set
associ
highrisk
nephrotox
immunosuppress
agent
use
prevent
reject
may
requir
minim
dose
reduct
immun
reconstitut
inflammatori
syndrom
iri
occur
even
immunosuppress
agent
dosereduc
antitb
treatment
revers
immunosuppress
effect
tb
screen
latent
tb
prior
exposur
tuberculosi
reactiv
caus
clinic
diseas
need
perform
pretranspl
lung
transplant
candid
two
test
avail
name
tuberculin
skin
test
tst
interferongamma
releas
assay
igra
igra
use
centr
screen
algorithm
avail
risk
reactiv
sever
infect
increas
transplant
recipi
annual
risk
activ
tb
posit
tst
good
argument
latent
tb
treatment
optim
time
latent
tb
treatment
pretranspl
latent
tb
treat
initi
boost
tst
produc
indur
mm
posit
igra
prior
histori
untreat
latent
tb
orreceipt
organ
donor
known
untreat
latent
tb
isoniazid
oral
pyridoxin
treatment
choic
low
risk
toxic
rifampicin
week
isoniazid
combin
rifapentin
week
altern
regimen
pretransplant
drug
interact
alreadi
state
persontoperson
transmiss
tb
occur
major
rout
inhal
airborn
particl
number
factor
increas
risk
transmiss
airborn
particl
includ
presenc
untreat
activ
pulmonari
laryng
tb
cavitari
diseas
smear
posit
short
time
posit
tuberculosi
cultur
number
procedur
also
increas
risk
dispers
airborn
particl
includ
intub
bronchoscopi
patient
extrapulmonari
tb
contagi
howev
concomit
pulmonari
laryng
tb
need
exclud
firstli
immunocompromis
patient
extrapulmonari
tb
presum
pulmonari
tb
proven
otherwis
numer
intern
nation
tb
control
guidelin
hospit
base
infect
control
program
tb
tb
suspect
untreat
patient
must
manag
airborn
isol
room
neg
pressur
ventilationmask
must
worn
healthcar
worker
contact
patient
patient
hesh
leav
roomwhen
tb
exclud
patient
remov
isolationfor
patient
confirm
tb
isol
discontinu
patient
receiv
treatment
demonstr
clinic
respons
three
neg
afb
smear
sputumclos
liaison
institut
infect
control
team
essenti
case
suspect
untreat
tb
treatment
similar
immunocompet
popul
multidrug
regimen
use
see
tabl
howev
similar
tb
specif
point
need
consid
transplant
settingsuscept
test
perform
direct
initi
mainten
regimen
clarithromycin
increas
serum
level
calcineurin
inhibitor
rapamycin
agent
via
cytochrom
cyp
pathway
initi
cessat
clarithromycin
immunosuppress
agent
may
need
dose
adjust
close
monitor
immunosuppress
concentr
requiredth
issu
outlin
rifamycin
use
tb
treatment
also
appli
treatment
ntmthe
durat
treatment
longer
immunocompet
popul
minimum
usual
month
last
posit
cultur
lifelong
suppress
therapi
may
need
patientsreduct
immunosuppress
need
consideredsurg
resect
may
requir
larg
abscess
presentther
larg
burden
diseasefoc
diseas
respond
therapyth
patient
toler
therapi
particular
problem
lung
transplant
set
increas
incid
caus
dissemin
infect
postlung
transplant
difficult
erad
also
resist
mani
avail
antimicrobi
agent
drugrel
toxic
detect
postlung
transplant
treatment
complic
prolong
centr
isol
abscessu
lung
transplant
candid
consid
strong
rel
contraind
transplant
centr
determin
transplant
patient
pretranspl
isol
abscessu
possibl
precaut
outlin
tabl
current
expert
opinion
indic
transplant
pretranspl
isol
abscessu
decid
casebycas
basi
ntm
ubiquit
environ
transmiss
usual
environment
sourc
addit
ntm
resist
chlorin
abil
form
biofilm
result
infect
control
measur
direct
ensur
adequ
disinfect
hospit
equip
rigor
repeat
surfac
clean
highqual
water
suppli
ongo
environment
surveil
hospit
set
close
liaison
institut
infect
control
engin
team
critic
prevent
outbreak
ntm
particularli
set
construct
evid
literatur
associ
persontoperson
transmiss
studi
indic
may
case
care
assess
institut
epidemiolog
assist
decid
patient
abscessu
requir
airborn
isol
simpli
rigor
clean
environ
recent
chimera
contamin
heatercool
unit
use
cardiac
surgeri
report
result
case
surgicalsit
dissemin
infect
worldwid
new
enhanc
decontamin
strategi
develop
ongo
surveil
requir
ensur
remain
effect
antibiot
mainstay
treatment
site
burden
infect
speci
potenti
drugdrug
interact
determin
antimicrobi
regimen
use
treatment
mild
pulmonari
trimethoprimsulfamethoxazol
tmpsmx
weekssever
pulmonari
infect
cn
involv
treatment
tmpsmx
plu
amikacincn
infectionparenter
treatment
tmpsmx
plu
imipenemmultiorgan
infect
includ
iv
amikacin
ad
regimen
iv
tmpsmx
imipenemmeropenem
may
use
instead
imipenem
former
less
like
precipit
seizur
activ
sensit
meropenem
must
demonstr
laboratori
use
linezolid
excel
vitro
activ
nocardia
use
success
treatment
therefor
linezolid
may
use
part
multidrug
regimen
patient
tmpsmx
allergi
desensitis
perform
possibl
parenter
treatment
continu
week
follow
oral
therapi
month
oral
agent
commonli
use
includ
tmpsmx
minocyclin
andor
amoxicillinclavulan
surgeri
may
requir
case
cerebr
nocardiosi
larg
soft
tissu
abscess
respond
treatment
empyema
mediastin
fluid
collect
pulmonari
nocardiosi
complic
pericard
consider
given
reduc
immunosuppress
especi
case
sever
diseas
progress
antimicrobi
treatment
indefinit
secondari
prophylaxi
also
recommend
immunosuppress
fulli
revers
report
persontoperson
transmiss
nocardia
literatur
nocardia
ubiquit
environment
organ
acquisit
mostli
environment
sourc
similar
ntm
infect
control
measur
hospit
set
nocardia
direct
disinfect
equip
surfac
ensur
highqual
water
suppli
ongo
surveil
requir
prevent
outbreak
particularli
set
construct
fungal
infect
signific
problem
lung
transplant
recipi
occur
caus
death
infect
major
infect
caus
candida
speci
third
common
caus
fungal
infect
fungi
caus
mucormycosi
eg
rhizopu
speci
scedosporium
fusarium
emerg
associ
high
mortal
rate
thu
increas
emphasi
place
earli
recognit
diagnosi
treatment
histoplasma
coccidioid
blastomyc
speci
import
live
previous
resid
visit
endem
area
whilst
infrequ
caus
signific
morbid
mortal
risk
factor
infect
similar
describ
bacteri
infect
addit
fungal
infect
implic
trigger
develop
chronic
reject
chronic
lung
allograft
dysfunct
clad
fungi
major
problem
lung
transplant
recipi
import
think
fungi
lung
transplant
recipi
suspect
infect
overestim
earli
diagnosi
treatment
critic
optimis
outcom
prophylaxi
may
reduc
impact
fungal
infect
lung
transplant
recipi
issu
drug
intoler
drugdrug
interact
emerg
resist
may
complic
treatment
reduc
overal
efficaci
common
aspergillu
speci
speci
caus
infect
lung
transplant
set
includ
flavu
terreu
niger
nidulan
import
identifi
terreu
differ
suscept
profil
aspergillu
speci
resist
amphotericin
b
aspergillu
speci
commonli
caus
type
infect
lung
transplant
recipi
aspergillu
colonis
tracheobronchi
aspergillosisinvas
pulmonari
aspergillosi
ipa
also
known
aspergillu
pneumonia
dissemin
invas
aspergillosi
ia
centr
give
antifung
agent
lung
transplant
recipi
immedi
posttranspl
month
minim
aspergillu
colon
complic
use
univers
prophylaxi
time
aspergillu
colonis
lengthen
month
month
postlung
transplant
centr
give
antifung
treatment
month
aspergillu
detect
known
preemptiv
strategi
known
strategi
best
treatment
choic
voriconazol
altern
agent
includ
amphotericin
b
posaconazol
itraconazolecombin
nebul
amphotericin
b
direct
local
effect
repeat
bronchoscop
debrid
particularli
larg
amount
necrot
debri
stent
occasion
requir
maintain
patent
airway
durat
treatment
depend
sever
initi
infect
degre
immunosuppress
respons
therapi
given
lesion
complet
heal
potenti
lifelong
bronchial
anastomot
involv
voriconazol
treatment
choic
echinocandin
anidulafungin
caspofungin
micafungin
ad
synergi
extens
diseas
unwel
eg
hypox
present
treatment
dissemin
diseas
ipa
ipa
treatment
continu
complet
resolut
import
rememb
give
voriconazol
azol
antifung
agent
lung
transplant
recipi
signific
interact
immunosuppress
eg
tacrolimu
cyclosporin
sirolimu
dose
adjust
immunosuppress
requir
initi
cessat
voriconazol
azol
regular
monitor
serum
immunosuppress
level
requir
specif
infect
control
measur
requir
echinocandin
liposom
amphotericin
b
treatment
candidaemia
seriou
candida
infect
candida
detect
sensit
profil
known
antifung
therapi
alter
isol
sensit
fluconazol
chang
agent
recommend
candida
caus
symptomat
infect
urinari
tract
echinocandin
recommend
poor
penetr
urinari
tract
set
fluconazol
isol
sensit
amphotericin
b
combin
isol
fluconazoleresist
recommend
specif
infect
control
requir
antifung
agent
use
depend
site
burden
infect
indic
diagnosisexclus
cn
diseas
ct
scan
mri
scan
head
lumbar
punctur
cultur
cryptococc
antigen
test
ct
chest
determin
extent
diseas
critic
importantcn
infect
dissemin
infect
sever
lung
amphotericin
b
minimum
week
follow
fluconazol
high
dose
week
fluconazol
lower
dose
month
year
recommendedsmal
volum
pulmonari
alon
month
recommend
specif
infect
control
requir
view
aggress
natur
fungu
high
mortal
rate
treatment
requir
multiprong
approachantifung
therapyfirstlin
therapi
liposom
amphotericin
bcaspofungin
ad
infect
severeposaconazol
isavuconazol
given
mainten
therapi
patient
intoler
liposom
amphotericin
bsurgic
debrid
necrot
tissu
fig
reduct
immunosuppressionrevers
underli
factor
eg
diabet
mellitu
specif
infect
control
measur
requir
scedosporium
innat
resist
mani
avail
antifung
agent
includ
amphotericin
bs
apiospermum
sensit
azol
antifung
agent
particularli
voriconazolea
combin
voriconazol
terbinafin
may
option
prolifican
known
lomentospora
prolifican
specif
infect
control
measur
requir
voriconazol
effect
agent
specif
infect
control
measur
requir
mild
sever
b
specif
infect
control
measur
requir
focal
pneumonia
treat
fluconazolediffus
diseas
treat
initi
amphotericin
b
clinic
respons
follow
fluconazol
itraconazolecoccidioid
mening
treat
fluconazol
specif
infect
control
measur
requir
liposom
amphotericin
b
clinic
improv
follow
oral
itraconazol
specif
infect
control
measur
requir
trimethoprimsulfamethoxazol
tmpsmx
mgkg
base
trimethoprim
compon
intraven
oral
divid
dose
daili
recommend
firstlin
treatmentif
patient
allerg
tmpsmx
desensit
perform
possibleif
tmpsmx
use
altern
includ
tmp
combin
dapson
primaquin
combin
clindamycin
atovaquon
intraven
pentamidineadjunct
corticosteroid
recommend
arteri
blood
gase
show
partial
pressur
oxygen
mmhg
like
treatment
pjp
firstlin
agent
prophylaxi
tmpsmp
lower
dose
doublestrength
tablet
time
week
singlestrength
tablet
daili
altern
includ
dapson
atovaquon
aerosol
pentamidin
sever
cluster
outbreak
pjp
report
particularli
renal
transplant
patient
cluster
outbreak
persontoperson
transmiss
postul
caus
consequ
hospitalis
patient
pjp
place
room
immunocompromis
patient
otherwis
standard
precaut
appli
review
clearli
illustr
fungi
major
problem
lung
transplant
recipi
import
think
fungi
lung
transplant
recipi
suspect
infect
underestim
earli
diagnosi
treatment
critic
optimis
outcom
prophylaxi
may
reduc
impact
fungal
infect
lung
transplant
recipi
issu
drug
intoler
drugdrug
interact
emerg
resist
may
complic
reduc
overal
efficaci
multicentr
research
requir
determin
optim
prophylact
strategi
lung
transplant
recipi
virus
organ
much
smaller
bacteria
unabl
detect
routin
microscopi
abl
surviv
replic
within
live
cell
use
chemic
machineri
cell
reproduc
virus
contain
either
deoxyribonucl
acid
dna
ribonucl
acid
rna
import
dna
virus
set
transplant
includ
herpesviru
famili
whilst
rna
virus
includ
signific
respiratori
pathogen
viral
infect
either
primari
follow
reactiv
latent
viru
remain
import
caus
morbid
mortal
follow
lung
transplant
viral
cultur
extrem
labori
difficult
restrict
specialist
laboratori
increasingli
diagnosi
viral
infect
made
pcr
peripher
blood
affect
tissu
pcr
avail
member
herpesviru
famili
list
acyclovirvalaciclovirfamciclovirsuppress
therapi
may
appropri
frequent
recurrencesth
develop
resist
viru
uncommon
standard
precaut
appli
patient
activ
hsv
lesion
howev
contact
precaut
may
appli
healthcar
set
lesion
cover
day
post
initi
treatment
crust
occur
hsv
dissemin
contact
precaut
requir
lesion
dri
crust
immunocompromis
staff
care
patient
infect
staff
high
risk
clinic
area
requir
urgent
review
leav
redeploy
high
dose
acyclovirvalaciclovirfamciclovirganciclovirpotenti
role
zoster
immun
globulin
contact
precaut
patient
activ
vzv
lesion
day
postiniti
treatment
crust
occur
reduc
level
immunosuppressionno
good
data
support
role
antivir
therapi
acyclovir
ganciclovir
immunomodulatori
agent
anti
rituximab
resect
localis
lesion
specif
precaut
requir
despit
variou
approach
prevent
cmv
diseas
activ
infect
occur
transplant
recipi
treatment
option
includ
intraven
gancicloviror
valganciclovircmv
immunoglobulinreduct
immunosuppress
treatment
failur
due
develop
resist
viru
well
recognis
may
part
due
subtherapeut
dose
ganciclovirvalganciclovir
resist
may
detect
specif
test
genet
mutat
common
option
treat
resist
cmv
diseas
includ
altern
experiment
drug
foscarnetcidofovirleflunomidebrincidofovirmaribavirletermovir
specif
infect
control
measur
requir
limit
clinic
treatment
data
avail
ganciclovir
valganciclovir
foscarnet
appear
activ
laboratori
test
may
role
reduct
immunosuppress
specif
infect
control
measur
requir
minim
anecdot
data
control
trial
treatment
although
anticmv
drug
ganciclovir
foscarnet
cidofovir
may
effect
specif
infect
control
procedur
requir
antivir
drug
appear
clinic
effect
mainstay
treatment
includ
reduct
immunosuppress
revers
underli
immun
deficiencychemotherapyrituximab
castleman
diseas
specif
infect
control
procedur
requir
respiratori
virus
circul
within
commun
season
geograph
variabl
seriou
complic
uncommon
nonimmunocompromis
host
set
lung
transplant
respiratori
viru
infect
associ
secondari
bacteri
infect
acut
reject
chronic
graft
dysfunct
increas
suscept
respiratori
virus
lung
transplant
recipi
multifactori
includ
immunosuppress
impair
cough
reflex
poor
mucociliari
clearanc
alter
lymphat
drainag
direct
exposur
lung
allograft
environ
prospect
studi
compar
lung
transplant
recipi
respiratori
viru
infect
uninfect
recipi
demonstr
respiratori
viru
infect
greater
risk
acut
reject
bronchiol
obliteran
syndrom
death
import
respiratori
virus
includ
respiratori
syncyti
viru
rsv
influenzaparainfluenzahuman
metapneumoviru
hmpv
coronavirusrhinovirusadenoviru
respiratori
viral
infect
common
lung
transplant
recent
studi
lung
transplant
recipi
year
period
found
infect
rate
one
viral
infect
studi
period
asymptomat
carriag
uncommon
mainli
associ
coronavirusrhinoviru
hospitalis
rate
influenza
parainfluenza
virus
infect
control
precaut
respiratori
virus
includ
droplet
precaut
singl
room
mask
gown
glove
room
entri
asymptomat
hand
hygien
per
moment
staff
come
work
respiratori
ill
unwel
visitor
allow
patient
contact
chemoprophylaxi
may
administ
patient
follow
exposur
appropri
see
specif
virus
mani
microbiolog
laboratori
perform
respiratori
pathogen
pcr
diagnost
panel
includ
common
respiratori
virus
influenza
influenza
b
enteroviru
rhinoviru
coronaviru
hmpv
parainfluenza
adenoviru
rsv
nonvir
organ
includ
bordetella
pertussi
bordetella
parapertussi
mycoplasma
pneumonia
pneumocysti
jirovecii
test
gener
perform
nose
throat
swab
requir
nasopharyng
aspir
bronchial
wash
ribavirin
nucleosid
analogu
broad
rang
activ
mani
rna
virus
despit
lack
randomis
trial
data
cornerston
treatment
rsv
ribavirin
administ
way
oralintravenousaerosolis
neg
pressur
room
specif
equip
requir
advic
regard
administr
dose
regimen
sought
ribavirin
signific
toxic
primarili
haematolog
teratogen
long
halflif
standard
droplet
precaut
requir
patient
manag
singl
room
treatment
initi
transplant
patient
suspect
proven
influenza
ceas
altern
diagnosi
made
therapeut
option
includ
oseltamivir
oral
influenza
b
zanamivir
inhal
influenza
b
amantadin
oral
influenza
rimantadin
oral
influenza
chemoprophylaxi
offer
patient
known
expos
influenza
viru
either
hospit
commun
set
droplet
standard
precaut
durat
symptom
day
activ
influenza
treatment
randomis
studi
antivir
therapi
howev
report
publish
primarili
haematolog
set
suggest
ribavirin
either
oral
intraven
administ
may
effect
treatment
small
singl
centr
studi
rsv
piv
lung
transplant
recipi
indic
lung
transplant
patient
lower
respiratori
tract
paramyxovir
infect
treat
inhal
ribavirin
die
return
baselin
lung
function
droplet
standard
precaut
ribavirin
shown
activ
hmpv
vitro
anim
model
infect
howev
human
studi
hmpv
infect
perform
use
ribavirin
remain
controversi
case
report
support
ribavirin
therapi
concomit
intraven
immunoglobulin
ivig
improv
symptom
droplet
standard
precaut
specif
treatment
option
avail
decreas
immunosuppress
may
role
littl
data
support
droplet
standard
precaut
randomis
studi
treatment
anecdot
case
report
suggest
cidofovir
may
role
result
mix
droplet
standard
precaut
